Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JNJ

Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?

Johnson & Johnson has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

Stock Market Today: Dow Jones Futures Gain as Coca-Cola Jumps After Q2 Beat, S&P 500, Nasdaq 100 Decline—Boeing, Johnson & Johnson in Focus (UPDATED)

Stock Market Today: Dow Jones Futures Gain as Coca-Cola Jumps After Q2 Beat, S&P 500, Nasdaq 100 Decline—Boeing, Johnson & Johnson in Focus (UPDATED)

(Editor’s note: The headline, lede, futures, ETFs, stocks and economic data were updated.)

Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today

Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today

Intuitive Surgical stock sinks as FDA announces marketing authorization for Johnson & Johnson’s Ottava platform. Here’s why the news is largely bearish for ISRG shares.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

MarketBeat Week in Review – 07/13- 07/17

A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.

Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

Unusual Put Option Activity in Johnson & Johnson After JNJ Stock's Recent Runup

Today, there has been large and unusual put option activity in Johnson & Johnson (JNJ) after the stock's recent rise. The puts are out-of-the-money (OTM), implying that some investors believe JNJ could tank.

These 3 Dividend Stocks Could Boost Your Income This July

Realty Income, Johnson & Johnson, and Chevron offer yields ranging from 2.2% to 5.1% in July 2026, supported by analyst buy ratings and institutional accumulation.

inkl

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson Earnings Preview: What to Expect

Johnson & Johnson Earnings Preview: What to Expect

Johnson & Johnson is scheduled to report its second-quarter results next month, and analysts expect a single-digit earnings rise.

How to Hunt for Mega-Cap Value After the SpaceX IPO

How to Hunt for Mega-Cap Value After the SpaceX IPO

I'm not buying into SpaceX following the record-setting IPO. But I am looking for big value elsewhere. Here's how I start my search.

3 Dividend Kings That Earn Their Crown Every Quarter

3 Dividend Kings That Earn Their Crown Every Quarter

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

3 Dividend Kings to Buy Now to Replace the Social Security Income You're About to Lose

3 Dividend Kings to Buy Now to Replace the Social Security Income You're About to Lose

The Congressional Budget Office (CBO) released a report this year containing one number that should change how every American near retirement thinks about income. Here's 3 dividend stocks to replace that lost income.

Is Johnson & Johnson Stock Outperforming the Dow?

Is Johnson & Johnson Stock Outperforming the Dow?

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Are Wall Street Analysts Bullish on Johnson & Johnson Stock?

Are Wall Street Analysts Bullish on Johnson & Johnson Stock?

Johnson & Johnson has outperformed the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

JNJ stock is on track to rally higher after better-than-expected results. Cash flow and growth say this dividend story is reliable.

Get all your
news in one place.

100's of premium titles.
One news app.

Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14?

This Dividend King offers a rare mix of safety and upside heading into earnings.

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

A Q2 2026 Playbook for Navigating Market Uncertainty

For investors looking to rebalance in Q2, here are three stocks that combine growth and defense to help investors stay invested during volatile markets

What You Need To Know Ahead of Johnson & Johnson's Earnings Release

Johnson & Johnson is expected to announce its first-quarter results next month, and analysts are projecting a single-digit decline in its EPS.

Get all your
news in one place.

100's of premium titles.
One news app.

2 Safe Dividend Stocks to Buy and Hold Forever

These are two dividend stocks that you can confidently buy, hold, and forget about for decades.

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

Johnson & Johnson provides stability through decades of dividend growth while pivoting to high-margin medical technology to outperform the volatile market.

Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility

Resilient stocks and ETFs offering steady demand and dividend yields may help investors weather further market turbulence without abandoning equity exposure.

Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...

What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

1 2 3 4 5

People

205,102 stories

Jeffrey Neal Johnson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

British Airways

Berkshire Hathaway

Amazon.com Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Social Security

Medical Technology

Places

402,431 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play